DOCSLIB.ORG

Antiviral and Related Nucleoside Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antiviral and Related Nucleoside Drugs Antiviral and Related Nucleoside Drugs The current outbreak of the novel coronavirus 2019-nCoV, a single-stranded positive-sense RNA (+ssRNA) virus, urges researchers to explore more efficient antiviral drugs. Granlen has almost 60 antiviral nucleoside drugs that could be the candidates in this arena. Hundreds of the closely related analogues are in stock for immediate biological tests and SAR studies. Our teams are ready to make further derivatives to support. NH2 GL100199 N CAS#123402-20-0 HO N O Antiviral agent O 3’-Deoxy-3’-fluorocytidine F OH O GL100612 N NH HO N N NH CAS#123402-21-1 O 2 Antiviral agent 3’-Deoxy-3’-fluoroguanosine F OH O I GL100224; CAS#69123-98-4 NH HO N O 5-Iodo-2’-deoxy-2’-fluoro-beta-D- O HBV drug, Fialuridine arabinouridine FIAU F HO GL100222, CAS#69123-94-0 O NH FAU, antiviral and anticancer 2’-Deoxy-2’-fluoro--D-arabinouridine, 2’- HO N O O F agent Fluoro-2’-deoxyuracyl--D-arabinofuranoside HO O H3C GL100900 NH HO N O CAS#69256-17-3; 2’-Deoxy-2’-fluoro-5- O HBV drug Clevudine methyl-beta-D-arabinouridine; FMAU F HO NH2 I GL100674 N antiviral drug, Fiacitabine; anti- HO N O CAS#69123-90-6; 5-Iodo-2’-deoxy-2’-fluoro- O infective therapy; antitumor beta-D-arabinocytidine, FICA F agent HO NH2 GL102999 N HO N O CAS#1011529-10-4 O Antiviral drug Azvudine F N3 4’-Azido-2’-deoxy-2’-fluoroaracytidine HO NH2 GL100575 N N antiviral agent; Protozoan parasite HO N N CAS#20227-41-2 O T. vaginalis inhibitor; Antisense 2’-Deoxy-2’-fluoroarabinoadenosine, 2’F-araA F target RNase HO O GL100617 NH HO N O CAS#31448-54-1 O Antiviral agent (TBEV) CH3 2’--C-Methyl uridine OH OH NH2 GL100619 N Antiviral agent; HCV drug HO N O CAS#20724-73-6 O CH3 NM107 2’-C-Methyl cytidine OH OH O GL102998 NH HO N O CAS#863329-66-2 O antiviral agent CH3 (2’R)-2’-Deoxy-2’-fluoro-2’-methyluridine HO F O O NH GL103019 O O HN P O N O CAS#1190307-88-0 O O HCV drug CH3 Sofosbuvir HO F NH2 GL100687 N N HCV and antiviral agent, RdRp HO N N CAS#15397-12-3 O CH3 inhibitor 2’--C-Methyladenosine HO OH 1 NH2 GL100640 N HO HCV replication inhibitor; N N CAS#443642-29-3 O CH3 antiviral agent 2’-beta-C-methyl tubercidin; MRK608 HO OH O GL100898 N NH HO N N CAS#374750-30-8 O NH2 Antiviral agent, HCV inhibitor 2’-C-beta-Methylguanosine CH3 HO OH O GL100823 NH HO N O CAS#215176-58-2 O Antiviral agent 3’-Azido-3’-deoxy-5-methyuridine N3 OH GL101276 NH2 N Ribonucleotide reductase CAS#51034-68-5 HO N O O inhibitor; antiviral agent 2’-Azido-2’-deoxycytidine HO N 3 NH2 GL100826 N N HO N N CAS#58699-62-0 O Antiviral antineoplastic agent 3’-Azido-3’-deoxyadenosine N3 OH O H C GL101268 3 NH HO N O CAS#108630-07-5 O Anticancer antiviral agent 3’-Amino-3’-deoxy-5-methyluridine H N OH 2 NH2 GL100226 N Balpiravir, HCV RdRp NS5B HO N O CAS#478182-28-4 O polymerase inhibitor, treat N3 4’-alpha-Azido-cytidine, R-1479 HO dengue virus infection OH H3C NH GL100909 O- N N+ HO CAS#113509-54-9 N N Antiviral agent O N6-Methyladenosine N1-oxide HO OH NH2 O- GL101125 N + N Antiviral and anti-inflammatory HO N N CAS#146-92-9 O 1 agent Adenosine N -Oxide HO OH GL102080 antiviral and immunosuppressive CAS#605-23-2 agents Arabinofuranosyl thymine NH2 GL101177 N N HO N N CAS#5536-17-4; Ara-adenosine O Antiviral Drug, Vidarabine 9-(-D-Arabinofuranosyl)adenine OH HO NC NH2 GL101581; CAS#606-58-6; Toyocamycin N antitumor antiviral antibiotics, HO N N 4-Amino-5-cyano-7-(-D-ribofuranosyl)-7H- O IRE1a inhibitor, PI3 kinase pyrrolo[2.3-d]pyrimidine inhibitor HO OH O NH2 GL101582; CAS#18417-89-5; Sangivamycin H2N N protein kinase inhibitor, antiviral HO 4-Amino-7-(-D-ribofuranosyl)-7H- N N O antimalarial agent pyrrolo[2.3-d]-pyrimidine-5-carboxamide HO OH O GL100970 NH HO N N CAS# 62160-23-0 O NH2 Antiviral agent, anti-HCV 7-Deazaguanosine OH HO HN GL100318 O N N HO CAS#4338-47-0 N N Anticancer and antiviral agent O N6-Furfuryladenosine HO OH 2 GL102055 HN N N antiviral agent, natural cytokinin CAS#4294-16-0 HO N N O nucleoside N6-Benzyladenosine HO OH GL102581 NH N N antiviral agent; plant cytokinin HO CAS#7724-76-7 N N O nucleoside N6-Isopentenyladenosine HO OH CF3 GL103080 HN N N Antiviral agent, cytokinin HO CAS#23661-03-2 N N O nucleoside N6-(3-Trifluoromethylbenzyl)adenosine HO OH HN GL103081 N N CF3 Antiviral agent, cytokinin HO N N CAS#722505-71-7 O 6 nucleoside N -(4-Trifluoromethylbenzyl)adenosine HO OH GL100209 natural antibiotics, antifungal CAS#14675-48-0; antiviral agent 6-Methylpurine-9-beta-D-riboside, 6-D-MPR O H N GL102583 2 NH CAS#2149-76-0 HO N O Anticancer antiviral agent O 5-Aminouridine HO OH O H CO GL100725 3 NH P2Y6 receptor agonist; RNA HO N O CAS#35542-01-9 O anticodon nucleoside for mRNA 5-Methoxyuridine vaccines OH OH O GL102027; CAS#36791-04-5 N NH2 HO N N 1--D-ribafuranosyl-1H-1,2,4-triazole-3- O HCV drug Ribavirin carboxamide OH OH NH2 GL101309 N HO N O CAS#7057-33-2 O Antiviral agent 3’-Deoxycytidine OH O GL102981 NH antiviral drug, Herpies simplex CAS#15176-29-1; 5-Ethyl-2’-deoxyuridine; HO N O O virus; DNA polymerase inhibitor Edoxudine (EUDR) HO O GL101962 HN OH CAS#5116-24-5 HO O N Antiviral and anticancer agent O 5-Hydroxymethyl-2’-deoxyuridine OH O I GL100246 NH N CAS#54-42-2 O O antiviral agent Idoxuridine, IDU HO 5-Iodo-2’-deoxyuridine HO O I GL100185; CAS#55612-21-0 NH HO N O 2’-Deoxy-2’-fluoro-5-iodouridine O antiviral agent 2’-epi-Fialuridine OH F O GL101122 NH HO N O CAS#41107-56-6 O Anti-HIV agent 2’,3’-Dideoxy-3’-fluorouridine, FddU F O GL101365 NH antiviral drug Alovudine, DNA CAS#25526-93-6 HO N O polymerase inhibitor, HIV-I O 3’-Deoxy-3’-fluoro-thymidine inhibitor F 3 O Cl GL101124 NH CAS#119644-22-3 HO N O Raluridine, HIV-1 inhibitor O 5-Chloro-2’,3’-dideoxy-3’-fluorouridine F NH2 GL101181 N CAS#51246-79-8 HO N O HIV inhibitor O 2’,3’-Dideoxy-3’-fluorocytidine; FddC F NH2 GL102596 N N HO N N CAS#87418-35-7 O anti-HIV agent 2’,3’-Dideoxy-3’-fluoroadenosine, 3’-F-ddA F O GL101956 NH HO N O CAS#84472-85-5 O HIV drug AZDU, AzddU 3’-Azido-2’,3’-dideoxyuridine; 3’-Azido-ddU N3 O GL101973 NH HIV drug Zidovudine, AZT, RT HO N O CAS#30516-87-1 O inhibitor, chain terminator, 3’-Azido-3-deoxythymidine N RdRp inhibitor 3 O HO GL102922 NH HO N O CAS#111495-90-0 O Anti-HIV agent 3’-Azido-2’,3’-dideoxy-5-hydroxyuridine N3 O GL100679; CAS#73971-82-1 NH 1-(3-beta-Azido-2,3-dideoxy-beta-D-threo HO N O HIV-1 replication inhibitor O pentafuranosyl)thymine N3 GL101976 O HN HIV drug Stavudine, RT, RdDp CAS#3056-17-5 HO O N O inhibitor 2’,3’-Dideoxy-2’,3’-didehydrothymidine, D4T GL101381 NH2 N CAS#7481-88-1 HO N O HIV-1 inhibitor, D4C O 2’,3’-Dideoxy-2’,3’-didehydro-cytidine, ddddC O GL101563 I NH 治疗单纯疱诊性病毒角膜炎 CAS#105784-83-6 HO N O O herpes simplex keratitis drug 5-Iodo-2’,3’-dideoxyuridine, IddU NH2 GL101391 F N CAS#134379-77-4; 2’,3’-Dideoxy-2’,3’- HO N O antiviral drug Dexelvucitabine didehydro-5-fluoro-cytidine O GL101382 NH2 N HIV drug Zalcitabine, RT/RdRp CAS#7481-89-2 HO N O O inhibitor 2’,3’-Dideoxycytidine, ddC NH2 GL101392 F N CAS#107036-62-4 HO N O HIV-1 inhibitor 2’,3’-Dideoxy-5-fluorocytidine, 5FddC O GL101975 O N NH HIV drug, didanosine, DDI, RT, CAS#69655-05-6 HO N N O RdDp inhibitor 2’,3’-dideoxyinosine GL102003 NH2 N CAS#4097-22-7 N antiviral drug, DDA HO N N O 2',3'-dideoxy adenosine Please contact Haoyun (Harry) An at [email protected] or Sherry Li at [email protected] or visit www.granlen.com for inquiries or additional questions 4 .
Load more

Recommended publications
  • Highlights of Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------------WARNINGS AND PRECAUTIONS--------------------­ These highlights do not include all the information needed to use • New onset or worsening renal impairment: Can include acute VIREAD safely and effectively. See full prescribing information renal failure and Fanconi syndrome. Assess creatinine clearance for VIREAD. (CrCl) before initiating treatment with VIREAD. Monitor CrCl and ® serum phosphorus in patients at risk. Avoid administering VIREAD (tenofovir disoproxil fumarate) tablets, for oral use VIREAD with concurrent or recent use of nephrotoxic drugs. (5.3) VIREAD® (tenofovir disoproxil fumarate) powder, for oral use • Coadministration with Other Products: Do not use with other Initial U.S. Approval: 2001 tenofovir-containing products (e.g., ATRIPLA, COMPLERA, and TRUVADA). Do not administer in combination with HEPSERA. WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH (5.4) STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS • HIV testing: HIV antibody testing should be offered to all HBV- infected patients before initiating therapy with VIREAD. VIREAD See full prescribing information for complete boxed warning. should only be used as part of an appropriate antiretroviral • Lactic acidosis and severe hepatomegaly with steatosis, combination regimen in HIV-infected patients with or without HBV including fatal cases, have been reported with the use of coinfection. (5.5) nucleoside analogs, including VIREAD. (5.1) • Decreases in bone mineral density (BMD): Consider assessment • Severe acute exacerbations of hepatitis have been reported of BMD in patients with a history of pathologic fracture or other in HBV-infected patients who have discontinued anti- risk factors for osteoporosis or bone loss. (5.6) hepatitis B therapy, including VIREAD. Hepatic function • Redistribution/accumulation of body fat: Observed in HIV-infected should be monitored closely in these patients.
    [Show full text]
  • COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
    antibiotics Article An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan Sayer Al-Azzam 1, Nizar Mahmoud Mhaidat 1, Hayaa A. Banat 2, Mohammad Alfaour 2, Dana Samih Ahmad 2, Arno Muller 3, Adi Al-Nuseirat 4 , Elizabeth A. Lattyak 5, Barbara R. Conway 6,7 and Mamoon A. Aldeyab 6,* 1 Clinical Pharmacy Department, Jordan University of Science and Technology, Irbid 22110, Jordan; [email protected] (S.A.-A.); [email protected] (N.M.M.) 2 Jordan Food and Drug Administration (JFDA), Amman 11181, Jordan; [email protected] (H.A.B.); [email protected] (M.A.); [email protected] (D.S.A.) 3 Antimicrobial Resistance Division, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland; [email protected] 4 World Health Organization Regional Office for the Eastern Mediterranean, Cairo 11371, Egypt; [email protected] 5 Scientific Computing Associates Corp., River Forest, IL 60305, USA; [email protected] 6 Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, UK; [email protected] 7 Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield HD1 3DH, UK * Correspondence: [email protected] Citation: Al-Azzam, S.; Mhaidat, N.M.; Banat, H.A.; Alfaour, M.; Abstract: Coronavirus disease 2019 (COVID-19) has overlapping clinical characteristics with bacterial Ahmad, D.S.; Muller, A.; Al-Nuseirat, respiratory tract infection, leading to the prescription of potentially unnecessary antibiotics. This A.; Lattyak, E.A.; Conway, B.R.; study aimed at measuring changes and patterns of national antimicrobial use for one year preceding Aldeyab, M.A.
    [Show full text]
  • Chapter 12 Antimicrobial Therapy Antibiotics
    Chapter 12 Antimicrobial Therapy Topics: • Ideal drug - Antimicrobial Therapy - Selective Toxicity • Terminology - Survey of Antimicrobial Drug • Antibiotics - Microbial Drug Resistance - Drug and Host Interaction An ideal antimicrobic: Chemotherapy is the use of any chemical - soluble in body fluids, agent in the treatment of disease. - selectively toxic , - nonallergenic, A chemotherapeutic agent or drug is any - reasonable half life (maintained at a chemical agent used in medical practice. constant therapeutic concentration) An antibiotic agent is usually considered to - unlikely to elicit resistance, be a chemical substance made by a - has a long shelf life, microorganism that can inhibit the growth or - reasonably priced. kill microorganisms. There is no ideal antimicrobic An antimicrobic or antimicrobial agent is Selective Toxicity - Drugs that specifically target a chemical substance similar to an microbial processes, and not the human host’s. antibiotic, but may be synthetic. Antibiotics Spectrum of antibiotics and targets • Naturally occurring antimicrobials – Metabolic products of bacteria and fungi – Reduce competition for nutrients and space • Bacteria – Streptomyces, Bacillus, • Molds – Penicillium, Cephalosporium * * 1 The mechanism of action for different 5 General Mechanisms of Action for antimicrobial drug targets in bacterial cells Antibiotics - Inhibition of Cell Wall Synthesis - Disruption of Cell Membrane Function - Inhibition of Protein Synthesis - Inhibition of Nucleic Acid Synthesis - Anti-metabolic activity Antibiotics
    [Show full text]
  • Antiviral Drug Resistance
    Points to Consider: Antiviral Drug Resistance Introduction Development of resistance to antimicrobial agents (including antivirals) is considered to be a natural consequence of rapid replication of microorganisms in the presence of a selective pressure. I.e. it is a natural evolutionary event and should be an expected outcome of the use of antimicrobial agents. The speed with which such resistant organisms develop, and their ability to persist in the population, will be influenced by several factors including the extent to which the antimicrobial agent is used, and the viability of the new (mutated) resistant organism. Microorganisms may also differ naturally in their sensitivity to antimicrobial agents, and the existence of such insensitivity can have an impact on emergence of resistance in two ways. (i) It provides evidence that drug resistant organisms are viable, and could therefore emerge and persist in the population in response to drug use. (ii) Use of antimicrobial agents may create an environment in which pre‐existing insensitive strains may have a selective advantage and spread. Background to drug resistant influenza viruses 1 Adamantanes (amantadine, rimantidine) The existence of viruses resistant or insensitive to this class of antiviral agent is well documented. Many of the currently circulating strains of virus (both human and animal) lack sensitivity to these agents, and clinical use of amantadine or rimantadine has been shown to select for resistant viruses in a high proportion of cases, and within 2‐3 days of starting treatmenti. Such rapid emergence of resistance during treatment may explain the reduced efficacy of rimantidine or amantadine prophylaxis when the index cases were also treatedii.
    [Show full text]
  • KALETRA® (Lopinavir/Ritonavir) Capsules (Lopinavir/Ritonavir) Oral Solution
    1 of 57 KALETRA® (lopinavir/ritonavir) capsules (lopinavir/ritonavir) oral solution DESCRIPTION Proprietary name: Kaletra Established name: lopinavir and ritonavir Route of administration: ORAL (C38288) Active ingredients (moiety): Lopinavir (Lopinavir), Ritonavir (Ritonavir) # Strength Form Inactive ingredients 1 133.3 MILLIGRAM, CAPSULE, FD&C Yellow No. 6, gelatin, glycerin, oleic acid, polyoxyl 35 castor oil, 33.3 MILLIGRAM LIQUID FILLED propylene glycol, sorbitol special, titanium dioxide, water (C42954) 2 80 MILLIGRAM, SOLUTION Acesulfame potassium, alcohol, artificial cotton candy flavor, citric acid, 20 MILLIGRAM (C42986) glycerin, high fructose corn syrup, Magnasweet-110 flavor, menthol, natural & artificial vanilla flavor, peppermint oil, polyoxyl 40 hydrogenated castor oil, povidone, propylene glycol, saccharin sodium, sodium chloride, sodium citrate, water KALETRA (lopinavir/ritonavir) is a co-formulation of lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV protease. As co-formulated in KALETRA, ritonavir inhibits the CYP3A- mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir. Lopinavir is chemically designated as [1S-[1R*,(R*), 3R*, 4R*]]-N-[4-[[(2,6- dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro- alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide. Its molecular formula is C37H48N4O5, and its molecular weight is 628.80. Lopinavir has the following structural formula: 2 of 57 Ritonavir is chemically designated as 10-Hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1- methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]. Its molecular formula is C37H48N6O5S2, and its molecular weight is 720.95. Ritonavir has the following structural formula: Lopinavir is a white to light tan powder.
    [Show full text]
  • Serious Adverse Drug Reactions at Two Children's Hospitals in South Africa
    Mouton et al. BMC Pediatrics (2020) 20:3 https://doi.org/10.1186/s12887-019-1892-x RESEARCH ARTICLE Open Access Serious adverse drug reactions at two children’s hospitals in South Africa Johannes P. Mouton1, Melony C. Fortuin-de Smidt1, Nicole Jobanputra1, Ushma Mehta2, Annemie Stewart1, Reneé de Waal2, Karl-Günter Technau3, Andrew Argent4, Max Kroon5, Christiaan Scott4 and Karen Cohen1* Abstract Background: The high HIV prevalence in South Africa may potentially be shaping the local adverse drug reaction (ADR) burden. We aimed to describe the prevalence and characteristics of serious ADRs at admission, and during admission, to two South African children’s hospitals. Methods: We reviewed the folders of children admitted over sequential 30-day periods in 2015 to the medical wards and intensive care units of each hospital. We identified potential ADRs using a trigger tool developed for this study. A multidisciplinary team assessed ADR causality, type, seriousness, and preventability through consensus discussion. We used multivariate logistic regression to explore associations with serious ADRs. Results: Among 1050 patients (median age 11 months, 56% male, 2.8% HIV-infected) with 1106 admissions we found 40 serious ADRs (3.8 per 100 drug-exposed admissions), including 9/40 (23%) preventable serious ADRs, and 8/40 (20%) fatal or near-fatal serious ADRs. Antibacterials, corticosteroids, psycholeptics, immunosuppressants, and antivirals were the most commonly implicated drug classes. Preterm neonates and children in middle childhood (6 to 11 years) were at increased risk of serious ADRs compared to infants (under 1 year) and term neonates: adjusted odds ratio (aOR) 5.97 (95% confidence interval 1.30 to 27.3) and aOR 3.63 (1.24 to 10.6) respectively.
    [Show full text]
  • Development and Effects of Influenza Antiviral Drugs
    molecules Review Development and Effects of Influenza Antiviral Drugs Hang Yin, Ning Jiang, Wenhao Shi, Xiaojuan Chi, Sairu Liu, Ji-Long Chen and Song Wang * Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou 350002, China; [email protected] (H.Y.); [email protected] (N.J.); [email protected] (W.S.); [email protected] (X.C.); [email protected] (S.L.); [email protected] (J.-L.C.) * Correspondence: [email protected] Abstract: Influenza virus is a highly contagious zoonotic respiratory disease that causes seasonal out- breaks each year and unpredictable pandemics occasionally with high morbidity and mortality rates, posing a great threat to public health worldwide. Besides the limited effect of vaccines, the problem is exacerbated by the lack of drugs with strong antiviral activity against all flu strains. Currently, there are two classes of antiviral drugs available that are chemosynthetic and approved against influenza A virus for prophylactic and therapeutic treatment, but the appearance of drug-resistant virus strains is a serious issue that strikes at the core of influenza control. There is therefore an urgent need to develop new antiviral drugs. Many reports have shown that the development of novel bioactive plant extracts and microbial extracts has significant advantages in influenza treat- ment. This paper comprehensively reviews the development and effects of chemosynthetic drugs, plant extracts, and microbial extracts with influenza antiviral activity, hoping to provide some refer- ences for novel antiviral drug design and promising alternative candidates for further anti-influenza drug development.
    [Show full text]
  • The Use of Antimicrobial and Antiviral Drugs in Alzheimer's Disease
    International Journal of Molecular Sciences Review The Use of Antimicrobial and Antiviral Drugs in Alzheimer’s Disease Umar H. Iqbal, Emma Zeng and Giulio M. Pasinetti * Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; [email protected] (U.H.I.); [email protected] (E.Z.) * Correspondence: [email protected]; Tel.: +1-212-241-7938 Received: 29 May 2020; Accepted: 10 July 2020; Published: 12 July 2020 Abstract: The aggregation and accumulation of amyloid-β plaques and tau proteins in the brain have been central characteristics in the pathophysiology of Alzheimer’s disease (AD), making them the focus of most of the research exploring potential therapeutics for this neurodegenerative disease. With success in interventions aimed at depleting amyloid-β peptides being limited at best, a greater understanding of the physiological role of amyloid-β peptides is needed. The development of amyloid-β plaques has been determined to occur 10–20 years prior to AD symptom manifestation, hence earlier interventions might be necessary to address presymptomatic AD. Furthermore, recent studies have suggested that amyloid-β peptides may play a role in innate immunity as an antimicrobial peptide. These findings, coupled with the evidence of pathogens such as viruses and bacteria in AD brains, suggests that the buildup of amyloid-β plaques could be a response to the presence of viruses and bacteria. This has led to the foundation of the antimicrobial hypothesis for AD. The present review will highlight the current understanding of amyloid-β, and the role of bacteria and viruses in AD, and will also explore the therapeutic potential of antimicrobial and antiviral drugs in Alzheimer’s disease.
    [Show full text]
  • Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
    pharmaceuticals Review Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection Isabella Zanella 1,2,* , Daniela Zizioli 1, Francesco Castelli 3 and Eugenia Quiros-Roldan 3 1 Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy; [email protected] 2 Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy 3 University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy; [email protected] (F.C.); [email protected] (E.Q.-R.) * Correspondence: [email protected]; Tel.: +39-030-399-6806 Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is spreading worldwide with different clinical manifestations. Age and comorbidities may explain severity in critical cases and people living with human immunodeficiency virus (HIV) might be at particularly high risk for severe progression. Nonetheless, current data, although sometimes contradictory, do not confirm higher morbidity, risk of more severe COVID-19 or higher mortality in HIV-infected people with complete access to antiretroviral therapy (ART). A possible protective role of ART has been hypothesized to explain these observations. Anti-viral drugs used to treat HIV infection have been repurposed for COVID-19 treatment; this is also based on previous studies on severe acute respiratory syndrome virus (SARS-CoV) and Middle East respiratory syndrome virus (MERS-CoV). Among Citation: Zanella, I.; Zizioli, D.; them, lopinavir/ritonavir, an inhibitor of viral protease, was extensively used early in the pandemic Castelli, F.; Quiros-Roldan, E.
    [Show full text]
  • Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patien
    1 2 3 PROJECT TITLE 4 Anti-viral Prophylaxis for Prevention of Cytomegalovirus (CMV) Reactivation in Immunocompetent 5 Patients in Critical Care 6 7 STUDY ACRONYM 8 Cytomegalovirus Control in Critical Care - CCCC 9 10 APPLICANTS 11 Dr Nicholas Cowley 12 Specialty Registrar Anaesthesia and Intensive Care Medicine, Intensive Care Research Fellow 13 Queen Elizabeth Hospital Birmingham 14 15 Professor Paul Moss 16 Professor of Haematology 17 Queen Elizabeth Hospital Birmingham 18 19 Professor Julian Bion 20 Professor of Intensive Care Medicine 21 Queen Elizabeth Hospital Birmingham 22 23 Trial Virologist Trial Statistician 24 Dr H Osman Dr P G Nightingale 25 Queen Elizabeth Hospital Birmingham University of Birmingham CCCC CMV Protocol V1.7, 18th September 2013 1 Downloaded From: https://jamanetwork.com/ on 09/23/2021 26 CONTENTS 27 Substantial Amendment Sept 18th 2013 4 28 1 SUMMARY OF TRIAL DESIGN .......................................................................................................... 5 29 2 QEHB ICU Duration of Patient Stay ................................................................................................. 6 30 3 SCHEMA - QEHB PATIENT NUMBERS AVAILABLE FOR RECRUITMENT ........................................... 6 31 4 INTRODUCTION ............................................................................................................................... 7 32 4.1 CMV latent infection is widespread ........................................................................................ 7 33 4.2 CMV Reactivation
    [Show full text]
  • Rational Design and Synthesis of New Nucleoside Analogues Bearing a Cyclohexane Core
    Rational Design and Synthesis of New Nucleoside Analogues Bearing a Cyclohexane Core Beatriz Domínguez Pérez Ph.D. Thesis Ph.D. in Chemistry Supervisors: Dr. Ramon Alibés Arqués Dr. Félix Busqué Sánchez Dr. Jean-Didier Márechal Departament de Química Facultat de Ciències 2015 Memòria presentada per aspirar al Grau de Doctor per Beatriz Domínguez Pérez Beatriz Domínguez Pérez Vist i plau, Dr. Ramon Alibés Arqués Dr. Félix Busqué Sánchez Dr. Jean-Didier Maréchal Bellaterra, 13 de maig de 2015 “When you make the finding yourself-even if you’re the last person on Earth to see the light- you’ll never forget it” Carl Sagan A mis padres, a mi hermana A Jonatan Table of contents Abbreviations................................................................................................................................ 1 I. General introduction ............................................................................................. 5 1. Viruses ................................................................................................................................. 7 1.1. Virus replication ............................................................................................................. 8 1.2. Viral diseases in humans ................................................................................................ 9 2. Antiviral drugs ................................................................................................................... 10 2.1. Nucleoside analogues .................................................................................................
    [Show full text]
  • Influenza Antiviral Medications: Summary for Clinicians
    Influenza Antiviral Medications: Summary for Clinicians The information on this page should be considered current for the 2014-2015 influenza season for clinical practice regarding the use of influenza antiviral medications. This page contains excerpts from Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza - Recommendations of the Advisory Committee on Immunization Practices (ACIP). PDF Version[1 MB, 28 pages] Antiviral medications with activity against influenza viruses are an important adjunct to influenza vaccine in the control of influenza. Influenza antiviral prescription drugs can be used to treat influenza or to prevent influenza. Four licensed prescription influenza antiviral agents are available in the United States. o Two FDA-approved influenza antiviral medications are recommended for use in the United States during the 2014-2015 influenza season: oral oseltamivir (Tamiflu®) and inhaled zanamivir (Relenza®). Oseltamivir and zanamivir are chemically related antiviral medications known as neuraminidase inhibitors that have activity against both influenza A and B viruses. o Amantadine and rimantadine are antiviral drugs in a class of medications known as adamantanes. These medications are active against influenza A viruses, but not influenza B viruses. As in recent past seasons, there continues to be high levels of resistance (>99%) to adamantanes among influenza A (H3N2) and influenza A (H1N1) pdm09 ("2009 H1N1") viruses. Therefore, amantadine and rimantadine are not recommended for antiviral treatment or chemoprophylaxis of currently circulating influenza A viruses. Antiviral resistance to oseltamivir and zanamivir among circulating influenza viruses is currently low, but this can change. Also, antiviral resistance can emerge during or after treatment in some patients (e.g., immunosuppressed).
    [Show full text]